Rhumbline Advisers Sells 1,752 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Rhumbline Advisers reduced its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 0.6% in the first quarter, according to its most recent filing with the SEC. The fund owned 310,568 shares of the biopharmaceutical company’s stock after selling 1,752 shares during the period. Rhumbline Advisers owned about 0.26% of Catalyst Pharmaceuticals worth $7,531,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $27,000. Park Square Financial Group LLC purchased a new position in Catalyst Pharmaceuticals during the 4th quarter worth $29,000. Farther Finance Advisors LLC increased its holdings in Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,495 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Catalyst Pharmaceuticals during the 4th quarter worth $65,000. Finally, Quarry LP purchased a new position in Catalyst Pharmaceuticals during the 4th quarter worth $104,000. 79.22% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on CPRX. Stephens restated an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Thursday, June 5th. Robert W. Baird raised their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, March 3rd. Finally, Wall Street Zen upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Six investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Catalyst Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $32.83.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $26.31 on Wednesday. The stock’s fifty day moving average price is $23.71 and its 200 day moving average price is $22.81. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.75 and a 1-year high of $26.58. The company has a market cap of $3.21 billion, a price-to-earnings ratio of 22.30, a price-to-earnings-growth ratio of 3.31 and a beta of 0.72.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the completion of the sale, the insider now owns 68,873 shares of the company’s stock, valued at approximately $1,627,468.99. The trade was a 38.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.40% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.